The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases

Expert Opinion on Drug Safety

Volumn 14, Issue 9, 2015, Pages 1387-1394

  Baker, Britain ^a   Eça Guimarães, Luísa ^a   Tomljenovic, Lucija ^b   Agmon Levin, Nancy ^a   Shoenfeld, Yehuda ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adjuvant; Aluminum; Autoimmune inflammatory syndrome induced by adjuvants; Autoimmunity; Guillain barr syndrome; Human papilloma virus; Postural orthostatic tachycardia syndrome; Premature ovarian failure; Vaccines

Indexed keywords

WART VIRUS VACCINE; ALUMINUM DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

AUTOIMMUNE DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; REVIEW; RISK BENEFIT ANALYSIS; WART VIRUS; ANIMAL; AUTOIMMUNE DISEASES; CHEMISTRY; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; AUTOIMMUNE DISEASES; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84939810396     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1073710     Document Type: Review

References (68)

1. Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: A review. Aust N Z J Obstet Gynaecol 2011; 51(2): 103-8
2. Paavonen J. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis 2007; 11(Suppl 2): S3-9
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90
4. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356(19): 1928-43
5. Balofsky A, Agmon-Levin N, Shoenfeld Y. The new H1N1 and HPV vaccines and old fears. Curr Opin Rheumatol 2010; 22(4): 431-6
6. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93(4): 284-92
7. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004; 364(9447): 1757-65
8. Tomljenovic L, Shaw CA. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds? Ann Med 2013; 45(2): 182-93
9. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 2007; 369(9576): 1861-8
10. Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95(11): 1459-66
11. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7. 3 years in young adult women. Vaccine 2010; 28(38): 6247-55
12. Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 2010; 10(50): 7-17
13. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9. 4 years post-vaccination. Hum Vaccin Immunother 2014; 10(8): 2147-62
14. Castle PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis 2004; 8(3): 224-30
15. Vaccine safety [Internet]. Available from: http: //www. who. int/vaccine-safety/en/ [Last accessed 25 April 2015]
16. Possible side-effects of vaccines. Internet Available from: http: //www. cdc. gov/ vaccines/vac-gen/side-effects. htm [Last accessed 25 April 2015]
17. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': A dangerous liaison? J Autoimmun 2000; 14(1): 1-10
18. Agmon-Levin N, Paz Z, Israeli E, et al. Vaccines and autoimmunity. Nat Rev Rheumatol 2009; 5(11): 648-52
19. Israeli E, Agmon-Levin N, Blank M, et al. Guillain-Barre syndrome- A classical autoimmune disease triggered by infection or vaccination. Clin Rev Allergy Immunol 2012; 42(2): 121-30
20. Tomljenovic L, Shaw CA. Adverse reactions to human papillomavirus (HPV) vaccines. In: Shoenfeld Y, Agmon-Levin N, Tomljenovic L, editors. 1st edition. Wiley Press; New York: 2015
21. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases-2008. Isr Med Assoc J 2008; 10(1): 8-12
22. Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol Res 2015; 92: 18-22
23. Feenstra B, Pasternak B, Geller F, et al. Common variants associated with general and MMR vaccine-related febrile seizures. Nat Genet 2014; 46(12): 1274-82
24. Pellegrino P, Falvella FS, Perrone V, et al. The first steps towards the era of personalised vaccinology: Predicting adverse reactions. Pharmacogenomics J 2015; 15(3): 284-7
25. Zivkovic I, Petrusic V, Stojanovic M, et al. Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant. Innate Immun 2012; 18(2): 333-42
26. Israeli E, Agmon-Levin N, Blank M, et al. Adjuvants and autoimmunity. Lupus 2009; 18(13): 1217-25
27. Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991; 133(9): 940-51
28. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National influenza immunization program, United States, 1976-1977. Am J Epidemiol 1979; 110(2): 105-23
29. Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med 2010; 9(45): 90-7
30. Zafrir Y, Agmon-Levin N, Paz Z, et al. Autoimmunity following hepatitis B vaccine as part of the spectrum of "Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants" (ASIA): Analysis of 93 cases. Lupus 2012; 21(2): 146-52
31. Shoenfeld Y, Agmon-Levin N. "ASIA"-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36(1): 4-8
32. Vera-Lastra O, Medina G, Cruz-Dominguez MDP, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol 2013; 9(4): 361-73
33. Agmon-Levin N, Hughes GR V, Shoenfeld Y. The spectrum of ASIA: "Autoimmune (Auto-inflammatory) syndrome induced by adjuvants". Lupus 2012; 21(2): 118-20
34. Perricone C, Agmon-Levin N, Shoenfeld Y. Novel pebbles in the mosaic of autoimmunity. BMC Med 2013; 11: 101
35. Gatto M, Agmon-Levin N, Soriano A, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013; 32(9): 1301-7
36. McCarthy JE, Filiano J. Opsoclonus Myoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord 2009; 15(10): 792-4
37. Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014; 13(3): 215-24
38. Agorastos T, Chatzigeorgiou K, Brotherton JML, et al. Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far. Vaccine 2009; 27(52): 7270-81
39. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302(7): 750-7
40. Macartney KK, Chiu C, Georgousakis M, et al. Safety of human papillomavirus vaccines: A review. Drug Saf 2013; 36(6): 393-412
41. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010; 29(2): 95-101
42. Labadie J. Postlicensure safety evaluation of human papilloma virus vaccines. Int J Risk Saf Med 2011; 23(2): 103-12
43. Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: A review. Expert Opin Drug Saf 2015; 14(5): 1-16
44. World Health Organization. Vaccine safety. Internet Available from: http: // www. who. int/vaccine-safety/committee/ topics/hpv/GACVS-Statement-HP V- 12-Mar-2014. pdf?ua=1 [Last accessed 3 June 2015]
45. World Health Organization. Weekly epidemiological record. Available from: http: //www. who. int/wer/2014/wer8943. pdf?ua=1
46. Souayah N, Michas-Martin PA, Nasar A, et al. Guillain-Barre syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006-2009. Vaccine 2011; 29(5): 886-9
47. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012; 271(2): 193-203
48. Slade BA, Gee J, Broder KR, et al. Comment on the contribution by Souayah et al. , "Guillain-Barre syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006-2009". Vaccine 2011; 29(5): 865-6
49. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine 2011; 29(46): 8279-84
50. Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc 2007; 82(3): 308-13
51. Blitshteyn S. Postural tachycardia syndrome after vaccination with Gardasil. Eur J Neurol 2010; 17(7): e52
52. Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol 2014; 21(1): 135-9
53. Brinth L, Theibel AC, Pors K, et al. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J 2015; 62(4): A5064
54. Kinoshita T, Abe R-T, Hineno A, et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med 2014; 53(19): 2185-200
55. Baker VL. Primary ovarian insufficiency in the adolescent. Curr Opin Obstet Gynecol 2013; 25(5): 375-81
56. Little DT, Ward HRG. Adolescent premature ovarian insufficiency following human papillomavirus vaccination: A case series seen in general practice. J Investig Med High Impact Case Reports 2014; 2: 4
57. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012; 166(12): 1140-8
58. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906
59. VAERS data [Internet]. Available from: https: //vaers. hhs. gov/data/index [Last accessed 25 April 2015]
60. Geier DA, Geier MR. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin Rheumatol 2015; 34(7): 1225-31
61. Soldevilla HF, Briones SFR, Navarra S V. Systemic lupus erythematosus following HPV immunization or infection? Lupus 2012; 21(2): 158-61
62. Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J 2013; 11: 29
63. Pellegrino P, Perrone V, Pozzi M, et al. The epidemiological profile of ASIA syndrome after HPV vaccination: An evaluation based on the vaccine adverse event reporting systems. Immunol Res 2015; 61(1-2): 90-6
64. Natale C, Giannini T, Lucchese A, et al. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol Cell Biol 2000; 78(6): 580-5
65. Bayas J-M, Costas L, Muñoz A. Cervical cancer vaccination indications, efficacy, and side effects. Gynecol Oncol 2008; 110(3 Suppl 2): S11-14
66. Hem SL. Elimination of aluminum adjuvants. Vaccine 2002; 20(Suppl 3): S40-3
67. Lee SH. Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil. J Inorg Biochem 2012; 117: 85-92
68. Lee S. Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after GardasilReg. vaccination- A case report. Adv Biosci Biotechnol 2012; 3(8): 1214-24